Shares of Oruka Therapeutics (ORKA) traded lower on Wednesday after updated data from a mid-stage trial for ORKA-001, its candidate for the autoimmune skin condition plaque psoriasis, fell short of expectations.

Announcing 28-week data from its EVERLAST-A Phase 2a trial, the